Cutaneous T-cell Lymphoma 
Welcome,         Profile    Billing    Logout  

164 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cutaneous T-cell Lymphoma
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Recruiting
4
20
RoW
Mogamulizumab
Kyowa Kirin China Pharmaceutical Co., Ltd.
Cutaneous T-Cell Lymphoma
10/25
01/26
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Active, not recruiting
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
09/24
09/24
ChiCTR2300074621: Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposome Combined With Duvelisib in Patients With Relapsed/Refractory PTCL and NK/T

Not yet recruiting
4
72
 
Mitoxantrone hydrochloride liposome and Duvelisib ;Mitoxantrone hydrochloride liposome and Duvelisib
Shandong Cancer Hospital; Shandong Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
lymphoma
 
 
2020-001992-34: Interview study after treatment for skin cancer with Galderma gel CD11301 to capture information about treatment benefit as perceived by patient Befragungsstudie nach der Behandlung von Hautkrebs mit Galderma Gel CD11301, um Informationen über den Nutzen der Behandlung aus Patientensicht zu erfassen.

Not yet recruiting
3
30
Europe
Resiquimod, CD11301, Gel
GALDERMA Research & Development LLC, GALDERMA Research & Development LLC
Cutaneous T Cell Lymphoma, Immune Cancer, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
FLASH2, NCT06470451: Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Not yet recruiting
3
80
NA
Hypericin, HyBryte, SGX301, Placebo
Soligenix
CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
07/26
10/26
TOTEM-01, NCT05205902: TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides

Not yet recruiting
3
78
NA
Low-dose total-skin electron-beam therapy, Phototherapy
Assistance Publique - Hôpitaux de Paris
Mycosis Fungoides, Cutaneous T Cell Lymphoma
02/27
02/31
ChiCTR-TNC-10000806: Study of Chidamide in Patients With Cutaneous T-cell Lymphoma

Completed
2
82
 
Oral Chidamide 30mg twice weekly
Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences Co., Ltd., Chipscreen Biosciences Co., Ltd.
Cutaneous T-cell lymphoma
 
 
NCT01534767: Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting
2
19
US
sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
06/13
10/13
NCT01414127: Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT

Active, not recruiting
2
22
US
tacrolimus, FK 506, Prograf, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell
Barbara Ann Karmanos Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
10/13
10/13
2014-001377-14: Treatment with pimecrolimus cream of early Stage Mycosis Fungoides. Tratamiento con pimecrolimus crema de la micosis fungoides en estadio precoz.

Ongoing
2
40
Europe
Pimecrolimus, Elidel 10 mg/g crema, Elidel 10 mg/g crema
Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, ISCIII, IIS del Hospital Universitario 12 de Octubre
Patients with Stages Ia-IIa of Mycosis Fungoides. Pacientes con micosis fungoide estadio Ia-IIa.
 
 
ACTRN12618000028202: A phase 2, open label trial of guadecitabine (SGI-110) in patients with T-cell lymphoma

Completed
2
20
 
Monash Health, ASTEX Pharmaceuticals Inc.
T-cell lymphoma
 
 
PARCT, NCT03357224: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)

Terminated
2
26
Europe
Atezolizumab, Tecentriq
European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
03/21
08/22
NCT03063632: Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Completed
2
28
US
Interferon Gamma-1b, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, IFNg-1b, Interferon gamma-1b, Recombinant, N(Sup 2)-L-Methionyl-1-139-Interferon G, N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced), Recombinant Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475
National Cancer Institute (NCI)
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
04/21
03/23
NCI-2018-00810, NCT03534180: Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

Completed
2
12
US
Laboratory Biomarker Analysis, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
04/21
07/23
NCT02362997: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Completed
2
82
US
Pembrolizumab, Keytruda, MK-3475, SCH 900475
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
10/21
06/23
Lemon-T, NCT03730740: Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma

Recruiting
2
79
RoW
Lenalidomide 25mg, Lenalidomide
Samsung Medical Center
Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma
11/21
11/23
NCT00896493: Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Completed
2
38
US
anti-thymocyte globulin, ATG, cyclosporine, cyclosporin, cyclosporin A, Lymphoid radiation, Total lymphoid irradiation (TLI)
Stanford University
Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Cutaneous T-cell Lymphoma
11/21
12/22
RV-CL-PTCL-PI-003974, NCT02232516: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Active, not recruiting
2
30
US
romidepsin, FK228, FR901228, Istodax, lenalidomide, CC-5013, IMiD-1, Revlimid, laboratory biomarker analysis
Northwestern University, Celgene, National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
08/20
08/24
ChiCTR2000033939: An open, single center, single arm phase II clinical study for Anlotinib Hydrochloride capsule in the treatment of peripheral T-cell lymphoma

Recruiting
2
30
 
arotinib hydrochloride capsule
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Zhengda Tianqing Pharmaceutical Group Co., Ltd
peripheral T-cell lymphoma
 
 
2019-000914-12: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors

Not yet recruiting
2
27
Europe
TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab/, Infusion, Injection, TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab)
University of Cologne, F. Hoffmann La Roche
• Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor)• Prostate carcinoma: castration-resistant, 2 lines of chemotherapy failed• CTCL: ≥ stage IIB, ≥ 2 previous lines of treatment, Patients with late stage Melanoma, Prostate carcinoma or Cutaneous T cell lymphoma (CTCL), Diseases [C] - Cancer [C04]
 
 
REDIRECT, NCT04101331 / 2019-001003-20: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Completed
2
108
Europe, US, RoW
AFM13
Affimed GmbH
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
05/22
01/24
NCT04296786: Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Recruiting
2
52
RoW
Sintilimab, Chidamide
Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Longfu Hospital, Dongzhimen Hospital, Beijing
Cutaneous T-cell Lymphoma
12/22
12/24
RESMAIN, NCT02953301 / 2016-000807-99: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

Active, not recruiting
2
201
Europe, Japan
resminostat, 4SC-201, Placebo
4SC AG
Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous
03/23
06/24
2021-005950-27: Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker

Not yet recruiting
2
20
Europe
[89Zr] - Brentuximab, Solution for injection
University Medical Center Groningen, Takeda Pharmaceutical Company Ltd
All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including:Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lymphoma, DLBCL Alle patiënten met histologisch bewezen CD30-positieve (d.w.z. > 1% cellen) lymfomen die zullen worden behandeld met brentuximab vedotin, waaronder: Hodgkin-lymfoom, T-cellymfoom, Cutaan T-cellymfoom, DLBC, Patients with Lymphoma Patiënten met lymfeklierkanker:, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
 
 
REACH, NCT04218825: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Terminated
2
2
Europe
chlormethine gel, Ledaga®
European Organisation for Research and Treatment of Cancer - EORTC
Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)
04/23
04/23
PORT, NCT03385226 / 2017-000433-30: A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

Active, not recruiting
2
46
Europe
Pembrolizumab, Chemical Abstract Service (CAS) number - 1374853-91-4, Radiotherapy
University College, London, Merck Sharp & Dohme LLC
Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome
09/23
09/24
2019-004891-20: Rash aEtiology After CHlormethine gel

Not yet recruiting
2
100
Europe
LEDAGA, Gel, LEDAGA
European Organisation for Research and Treatment of Cancer, EORTC, European Organisation for Research and Treatment of cancer, HELSINN HEALTHCARE SA, RECORDATI RARE DISEASES Sarl
Early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL), Cutaneous lymphoma, Diseases [C] - Cancer [C04]
 
 
ChiCTR2100042759: An Open-Label, Multicenter Phase II Study to Investigate the Efficacy and Safety of BEBT-908 in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting
2
130
 
Intravenous drip of BEBT-908
Cancer Hospital Chinese Academy of Medical Sciences; Guangzhou BeBetter Medicine Technology Co., LTD, Guangzhou BeBetter Medicine Technology Co.,LTD
Relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
 
 
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
10/24
NCT04217317: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Recruiting
2
12
US
CPI 613, devimistat, Bendamustine, Bendeka, Treanda, Bendamustine Hydrochloride
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
11/24
06/25
NCT04930653: Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Recruiting
2
34
US
Extracorporeal Photopheresis, Extracorporeal Photophoresis, photopheresis, Photophoresis, Mogamulizumab, Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
05/25
05/25
NCT06149247: HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Recruiting
2
10
US
Hypericin, HyBryte, SGX301, Mechlorethamine Topical Gel, Valchlor
Soligenix
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
04/24
05/24
NCT04312841: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Active, not recruiting
2
6
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Ohio State University Comprehensive Cancer Center, Merck Sharp & Dohme LLC
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
04/24
12/24
NCT04256018: Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Recruiting
2
30
US
Mogamulizumab, LD TSEBT, Low-Dose (LD) Total skin electron beam therapy (TSEBT)
Stanford University
Sezary Syndrome, Mycosis Fungoides
02/24
08/24
OSU-17204, NCT03409432: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Active, not recruiting
2
26
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
John Reneau
Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
04/24
04/24
NCT02978625: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Active, not recruiting
2
68
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Mammography, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Keratoacanthoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
09/25
09/25
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
NCI-2022-03831, NCT05357794: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Recruiting
2
30
US
Brentuximab vedotin, SGN-35, Adcetris
M.D. Anderson Cancer Center, Seagen Inc.
Mycosis Fungoides
06/24
06/24
NCT03695471: Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Active, not recruiting
2
9
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Mayo Clinic, National Cancer Institute (NCI)
Mycosis Fungoides, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8
10/24
10/24
NCT02974647: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Recruiting
2
82
US
Ruxolitinib
Memorial Sloan Kettering Cancer Center, Cornell University, Dana-Farber Cancer Institute, Thomas Jefferson University
Lymphoma
11/24
11/24
NCT03398161: Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Recruiting
2
50
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Localized Skin Lesion, Mycosis Fungoides
12/24
12/24
NCT04745234 / 2020-004537-20: Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Active, not recruiting
2
34
Europe, US
Mogamulizumab, 0761, KW0761, Poteligeo
Kyowa Kirin, Inc.
Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
05/25
05/25
RW-HPN-MF-01, NCT05872854: Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Recruiting
2
50
US
Hypericin, HyBryte, SGX301, Visible Light, Fluorescent light
Ellen Kim, MD, Soligenix
Cutaneous T Cell Lymphoma, Mycosis Fungoides
05/25
05/25
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/25
07/25
NCT04960618: Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Recruiting
2
28
US
Gemcitabine, Pembrolizumab
Memorial Sloan Kettering Cancer Center
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis Fungoides
07/25
07/25
NCT05956041: Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Recruiting
2
23
US
Pembrolizumab, Keytruda, Mogamulizumab, Poteligeo
University of Michigan Rogel Cancer Center, Merck Sharp & Dohme LLC, Hoosier Cancer Research Network
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
12/25
12/26
NCT05157581: Extracorporeal Photopheresis in Sezary Syndrome

Recruiting
2
15
US
Extracorporeal photopheresis (ECP), ECP, photopheresis, Methoxsalen Injection, Uvadex
Oleg E. Akilov, MD, PhD, Mallinckrodt
Sezary Syndrome
12/25
12/26
NCT05680558: Photopheresis in Early-stage Mycosis Fungoides

Recruiting
2
74
US
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, UVADEX® with THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
Columbia University, Mallinckrodt, Inc.
Cutaneous T Cell Lymphoma, Mycosis Fungoides
12/25
07/26
NCT01352520: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Checkmark In CD30+ MF/SS and LPD and in MF/SS with various degree of CD30 expression
Oct 2015 - Oct 2015: In CD30+ MF/SS and LPD and in MF/SS with various degree of CD30 expression
Checkmark P2 data-ASH
Nov 2012 - Nov 2012: P2 data-ASH
Checkmark P2 data (CTCL)
More
Active, not recruiting
2
79
US
SGN-35, Brentuximab vedotin
M.D. Anderson Cancer Center, Seagen Inc.
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
01/26
01/26
NCT04795869: Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Withdrawn
2
40
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Seagen Inc.
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
03/26
03/29
NCT05879458: Ritlecitinib in CTCL

Recruiting
2
20
US
Ritlecitinib
Icahn School of Medicine at Mount Sinai, Pfizer
CTCL, Mycosis Fungoides, Sezary Syndrome
04/26
04/26
NCT05996185: Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma

Not yet recruiting
2
36
US
Mogamulizumab, Poteligeo, DA-EPOCH Protocol, dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone
Yale University, Kyowa Kirin, Inc.
T Cell Lymphoma
08/26
08/27
MOGAT, NCT04128072 / 2019-004566-17: Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

Recruiting
2
43
Europe
Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), Mogamulizumab (subsequent cycles post TSEB)
European Organisation for Research and Treatment of Cancer - EORTC
Stage IB-IIB Cutaneous T-Cell Lymphoma
10/26
01/27
NCT05313243: Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Recruiting
2
43
US
Brentuximab vedotin, Adcetris, Pembrolizumab, Keytruda
Yale University, Merck Sharp & Dohme LLC
T-Cell Lymphoma
04/28
07/28
NCT04676087: Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Recruiting
1b/2
32
US
Extracorporeal Photopheresis, Extracorporeal Photophoresis, photopheresis, Photophoresis, Mogamulizumab, Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo, Quality-of-Life Assessment, Quality of Life Assessment
Emory University, National Cancer Institute (NCI)
Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
04/25
04/25
NCT00091208: CpG 7909 in Treating Patients With Cutaneous T-Cell Lymphoma

Active, not recruiting
1/2
US
agatolimod sodium
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Lymphoma
 
 
NCT01497795: A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma

Recruiting
1/2
16
US
Resiquimod gel (0.06%), Resiquimod gel (0.2%)
Abramson Cancer Center of the University of Pennsylvania
Cutaneous T Cell Lymphoma
06/13
06/13
2018-001656-35: Imaging of patient skin cancer using a new magnetic resonance scanning technology

Not yet recruiting
1/2
30
Europe
[1-13C]Pyruvate, [1-13C]Pyruvate, Concentrate and solvent for concentrate for solution for infusion
Dept.Dermotology , Aarhus University, Dept. Dermatology, Aarhus University
mycosis fungiodes, skin cancer, Diseases [C] - Cancer [C04]
 
 
2020-002090-10: Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human Study of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2, as a Single Agent and with Pembrolizumab in Treatment of Advanced Malignancies

Not yet recruiting
1/2
236
Europe
BI-1808, BI-1808, Concentrate for solution for infusion, KEYTRUDA®
BioInvent International AB, BioInvent International AB
Phase 1, Parts A and Part B of the trial will recruit subjects with all types of malignancies whose tumors have progressed after standard anticancer treatment.Phase 2a, Parts A and Part B of the trial will recruit patients with NSCLC, OC, and CTCL (specifically MF or SS)., Advanced solid tumors, Diseases [C] - Cancer [C04]
 
 
2022-000222-24: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA Estudio en fase I/II, abierto y multicéntrico para investigar la seguridad, farmacocinética y eficacia de CYC140, un inhibidor de PLK1 oral, en sujetos con tumores sólidos y linfomas avanzados

Not yet recruiting
1/2
330
Europe
CYC140, Capsule, hard
Cyclacel Pharmaceuticals, Cyclacel Limited
ADVANCED SOLID TUMORS AND LYMPHOMA Tumores sólidos y linfomas avanzados, ADVANCED SOLID TUMORS AND LYMPHOMA Tumores sólidos y linfomas avanzados, Diseases [C] - Cancer [C04]
 
 
NCT05269940: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Recruiting
1/2
70
RoW
ZX-101A
Nanjing Zenshine Pharmaceuticals
Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, CLL/SLL
04/23
07/24
NCT01755975: Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1/2
62
US
Romidepsin, Lenalidomide
Memorial Sloan Kettering Cancer Center, Saint Francis/Mount Sinai Regional Cancer Center, Weill Medical College of Cornell University, University of Nebraska, Celgene Corporation, Biologics, Inc.
Multiple Myeloma, Non-Hodgkin's Lymphoma
10/23
10/23
ChiCTR2100048948: A single-arm, open-label, multicenter Phase I/II clinical study evaluating CN401 in patients with relapsed/refractory peripheral T-cell lymphoma and NK/T-cell lymphoma

Not yet recruiting
1/2
18
 
400mg CN401 tablet ;600mg CN401 tablet ;800mg CN401 tablet
Beijing Cancer Hospital; Curon Biopharmaceutical (Shanghai) Co., Ltd., self-financed
Relapsed/refractory peripheral T-cell lymphoma and NK/T-cell lymphoma
 
 
IMAGINE, NCT05138458: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Suspended
1/2
40
US
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Myeloid Therapeutics
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
11/24
10/25
NCT03598998: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Active, not recruiting
1/2
13
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX
City of Hope Medical Center, National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
05/23
06/24
NCT04541017: Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Active, not recruiting
1/2
88
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magrolimab, Hu5F9-G4, ONO-7913, Mogamulizumab, Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
National Cancer Institute (NCI)
Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Mycosis Fungoides and Sezary Syndrome, Refractory Sezary Syndrome, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
06/25
06/25
BIOSELECT, NCT05538988: BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

Not yet recruiting
1/2
16
Canada
Cemiplimab, Libtayo
AHS Cancer Control Alberta
Mycosis Fungoides
02/25
03/26
NCT06037239: Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study

Recruiting
1/2
53
RoW
Linperlisib in combined with Chidamide
Peking Union Medical College Hospital
Cutaneous T-cell Lymphoma
07/24
07/25
NCT03278782: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Active, not recruiting
1/2
39
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
07/24
07/24
NCT04362007: A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Active, not recruiting
1/2
61
Japan
ASTX660
Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
09/24
09/24
NCT05475925: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Recruiting
1/2
69
Europe, US, RoW
DR-01
Dren Bio, Novotech
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Indolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI Tract, Other CD8+/NK Cell Driven Lymphoma Not Listed Above
12/24
12/25
NCI-2019-03536, NCT04074746: Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Active, not recruiting
1/2
30
US
Anti-CD30/CD16A Monoclonal Antibody AFM13, AFM13, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Genetically Engineered Lymphocyte Therapy
M.D. Anderson Cancer Center
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
04/25
04/25
NCT03011814: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Recruiting
1/2
62
US
Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
City of Hope Medical Center, National Cancer Institute (NCI)
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
06/25
06/26
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
08/25
08/40
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25
NCT05544968: CD30biAb-AATC for CD30+ Malignancies

Not yet recruiting
1/2
42
US
anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), CD30 biAb-AATC
Medical College of Wisconsin, Midwest Athletes Against Childhood Cancer
Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, Leukemia, Lymphoma
01/27
01/27
NCT04118868: Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Recruiting
1b
10
US
Pembrolizumab administered using the Sofusa® DoseConnect™, Keytruda® administered using Sofusa® DoseConnect™ device
Sorrento Therapeutics, Inc.
Mycosis Fungoides
01/24
03/24
NCT01727102: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Active, not recruiting
1
42
US
sunitinib malate, SU11248, sunitinib, Sutent, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
05/13
 
NCT01638533: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Active, not recruiting
1
37
Canada, US
Pharmacological Study, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic
National Cancer Institute (NCI), Celgene Corporation
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
11/18
03/25
NCT02168140: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed
1
16
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia
04/19
09/22
NCT02342782: Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
20
US
Yttrium Y 90 Basiliximab, 90Y Basiliximab, Carmustine, FDA 0345, BCNU, BiCNU, Etoposide, Lastet, VP-16, Cytarabine, CHX-3311, U-19920, Ara-C, Cytosar, Melphalan, Alkeran, L-PAM, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies
City of Hope Medical Center, National Cancer Institute (NCI)
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
09/20
12/24
NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting
1
18
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
01/21
01/37
NCT02512497: Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Recruiting
1
10
US
Romidepsin, Istodax, Depsipeptide, FK228, Busulfan, Busulfex, Myleran, Fludarabine, Fludarabine Phosphate, Fludara, Stem Cell Transplant, Thymoglobulin, ATG, Rabbit Antithymocyte Globulin, Rabbit Antilymphocyte Globulin, Rabbit ATG, rATG
Ohio State University Comprehensive Cancer Center, Celgene Corporation
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
12/22
12/22
GEN-602-CT-101, NCT03775525: Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Active, not recruiting
1
127
US
GZ17-6.02, Capecitabine, Xeloda
Genzada Pharmaceuticals USA, Inc., Translational Drug Development
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
05/23
12/23
NCT04136275: CAR-37 T Cells In Hematologic Malignancies

Completed
1
6
US
CAR-37 T cells
Marcela V. Maus, M.D.,Ph.D.
Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
09/23
03/24
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Active, not recruiting
1
106
Europe, US
Tinostamustine
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
11/23
12/23
NCT05728879: Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Not yet recruiting
1
30
US
APR-TD011 (RLF-TD011), Nexodyn AOS
Northwestern University
Cutaneous T Cell Lymphoma
12/26
12/26
NCT01588015: Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Completed
1
36
US
tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cytomegalovirus Infection, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Isolated Plasmacytoma of Bone, Monoclonal Gammopathy of Undetermined Significance, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
02/24
02/24
NCT02616965: A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Active, not recruiting
1
16
US
Romidepsin, Brentuximab vedotin
Fox Chase Cancer Center, Seagen Inc., Celgene Corporation
Cutaneous T-cell Lymphoma (CTCL)
02/23
12/24
LB1901-TCL-1001, NCT04712864: Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Active, not recruiting
1
50
US
LB1901
Legend Biotech USA Inc
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent, Peripheral T-Cell Lymphoma Recurrent
12/23
12/25
NCT02520791: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Active, not recruiting
1
21
Canada, US
Anti-ICOS Monoclonal Antibody MEDI-570, MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Stage IB Mycosis Fungoides AJCC v7, Stage II Mycosis Fungoides AJCC v7, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides AJCC v7, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides AJCC v7
08/23
02/25
NCT04774068: Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Active, not recruiting
1
5
US
Parsaclisib, (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, INCB 50465, INCB-50465, INCB050465, INCB50465, WHO 10589, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic
Walter Hanel
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Mycosis Fungoides, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Mycosis Fungoides, T-Cell Non-Hodgkin Lymphoma
12/24
12/24
NCT03240211: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Recruiting
1
37
US
Pembrolizumab, Keytruda, Pralatrexate, Folotyn, Decitabine, Dacogen
University of Virginia, Merck Sharp & Dohme LLC, Otsuka Pharmaceutical Development & Commercialization, Inc.
PTCL, CTCL
06/25
12/25
NCT04848064: Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recruiting
1
12
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Mogamulizumab, Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo, Natural Killer Cell Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
John Reneau
Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
12/24
12/24
PLIGHT, NCT06235281: Phototherapy and Mogamulizumab in Early Stage MF

Recruiting
1
20
US
Mogamulizumab-Kpkc, POTELIGEO, Phototherapy, nb-UVB
H. Lee Moffitt Cancer Center and Research Institute, Kyowa Hakko Kirin Pharma, Inc.
Mycosis Fungoides
09/26
09/29
NCT05296304: A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

Recruiting
1
20
US
Bexarotene, Targretin®, Total Skin Electron Beam (TSEB)
Memorial Sloan Kettering Cancer Center
Cutaneous T-cell Lymphoma
03/25
03/25
ETCTN 10500, NCT05627245: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Recruiting
1
64
US
Belinostat, Beleodaq, PXD 101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Positron Emission Tomography and Computed Tomography Scan, PET-CT Scan, PET/CT SCAN, Positron Emission Tomography/Computed Tomography, Tazemetostat, E7438, EPZ-6438, EPZ6438
National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
03/25
03/25
NCT02783625: Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Checkmark In combination with romidepsin in r/r peripheral T-cell lymphoma
Dec 2018 - Dec 2018: In combination with romidepsin in r/r peripheral T-cell lymphoma
Hourglass May 2018 - May 2018 : P1 trial in relapsed/refractory T-cell lymphoma in combination with Velcade or Istodax
Active, not recruiting
1
114
US
Romidepsin, Bortezomib, duvelisib, IPI-145
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Stanford University
Lymphoma, Relapsed/Refractory T-cell Lymphomas
05/24
05/24
CRIMSON-NE, NCT03690011: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

Recruiting
1
27
US
CD7.CAR/28zeta CAR T cells
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
05/25
05/40
MNA-D, NCT02192021: Micro Needle Array-Doxorubicin () in Patients With Cutaneous T-cell Lymphoma (CTCL)

Active, not recruiting
1
20
US
Micro needle array-Doxorubicin (MNA-D), patch, doxorubicin
Falo, Louis, MD
Cutaneous T Cell Lymphoma
06/24
06/25
 

Download Options